Azra Raza
#21,431
Most Influential Person Now
Columbia University medical researcher
Azra Raza's AcademicInfluence.com Rankings
Azra Razabiology Degrees
Biology
#3656
World Rank
#5556
Historical Rank
Cell Biology
#785
World Rank
#802
Historical Rank
Azra Razaphilosophy Degrees
Philosophy
#8632
World Rank
#12045
Historical Rank
Logic
#7175
World Rank
#8847
Historical Rank
Download Badge
Biology Philosophy
Azra Raza's Degrees
- Masters Medicine King Edward Medical University
- PhD Cell Biology University of Chicago
Why Is Azra Raza Influential?
(Suggest an Edit or Addition)According to Wikipedia, Azra Raza is the Chan Soon-Shiong Professor of Medicine and Director of Myelodysplastic Syndrome Center at Columbia University. She has previously held positions at Roswell Park Comprehensive Cancer Center, University of Cincinnati, Rush University, and the University of Massachusetts. Raza's research focuses on myelodysplastic syndrome and acute myeloid leukemia.
Azra Raza's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. (2012) (1638)
- Decitabine improves patient outcomes in myelodysplastic syndromes (2006) (1434)
- Clinical effect of point mutations in myelodysplastic syndromes. (2011) (1433)
- Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. (2006) (965)
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screen (2007) (902)
- Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. (1995) (458)
- Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. (2012) (436)
- Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts (2014) (429)
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. (2008) (401)
- Myelodysplastic syndromes (2007) (372)
- Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. (2001) (322)
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I (2013) (287)
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial (2017) (278)
- Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. (2016) (278)
- Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. (2013) (275)
- MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia (1990) (187)
- Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities (2015) (178)
- An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome (2008) (170)
- Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. (2012) (166)
- Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. (1995) (165)
- Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis (1995) (156)
- Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986 (1989) (154)
- Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. (1996) (146)
- The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes (2012) (142)
- The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes (2001) (120)
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I (2013) (115)
- Anti‐TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes (2000) (113)
- Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. (2014) (111)
- U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. (2016) (110)
- Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. (2009) (108)
- Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. (2008) (107)
- Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. (2011) (107)
- Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies (2016) (107)
- A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (2007) (106)
- Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. (1987) (106)
- Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. (2008) (105)
- Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. (1990) (101)
- Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. (1987) (93)
- Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. (1996) (91)
- Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. (2000) (88)
- Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome (2002) (87)
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis (2013) (82)
- Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. (2008) (82)
- Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats (2009) (81)
- Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". (2007) (80)
- Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. (2004) (80)
- High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. (1987) (79)
- Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features (2006) (77)
- Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q (2007) (76)
- A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31 (2001) (72)
- Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. (2000) (71)
- A paradigm shift in myelodysplastic syndromes. (1996) (69)
- A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia (2014) (66)
- Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes (1999) (65)
- Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. (2009) (64)
- Combination of 5‐azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia (2008) (63)
- Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1. (2019) (61)
- Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes (2004) (60)
- Increased incidence of mitochondrial cytochrome c‐oxidase gene mutations in patients with myelodysplastic syndromes (2002) (60)
- Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial (2009) (59)
- Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies (2019) (57)
- Evidence for involvement of tumor necrosis factor‐α in apoptotic death of bone marrow cells in myelodysplastic syndromes (1999) (57)
- Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome (2009) (55)
- Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. (1999) (53)
- Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. (1997) (53)
- Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside (1984) (52)
- Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes (2013) (51)
- Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. (1989) (51)
- Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy (2015) (50)
- Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. (2020) (49)
- Chromosomes and causation of human cancer and leukemia. LIV. Near-tetraploidy in acute leukemia. (1985) (48)
- Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification (2008) (47)
- High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study (1986) (45)
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies (2014) (44)
- Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS) (2016) (44)
- Detection of monosomy 7 in interphase cells of patients with myeloid disorders (1990) (43)
- The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. (1996) (43)
- First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). (2004) (43)
- A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure (2013) (43)
- The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. (2000) (43)
- Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements (1986) (41)
- A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome (2012) (41)
- Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. (2006) (41)
- Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. (2008) (40)
- Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. (1999) (40)
- P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients (2001) (39)
- Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. (1997) (38)
- Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study (2005) (38)
- Tetrasomy of chromosome 8: an interesting and rare cytogenetic phenomenon in acute nonlymphocytic leukemia. (1987) (38)
- Extensive apoptosis of bone marrow cells as evaluated by the in situ end‐labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes (1999) (37)
- Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. (1991) (36)
- Defining the dynamics of self-assembled Fas-receptor activation. (2002) (36)
- Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I (2012) (36)
- A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. (2014) (35)
- Relationship between the per cent of marrow cells in S phase and the outcome of remission‐induction therapy for acute nonlymphocytic leukaemia (1984) (35)
- DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia (2011) (35)
- The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. (1999) (35)
- AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIA IN REMISSION (1987) (34)
- Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS) (2008) (33)
- Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. (1999) (32)
- Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. (1997) (32)
- MicroRNAs in myeloproliferative neoplasms (2013) (32)
- Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. (2001) (32)
- Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I (2011) (31)
- Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. (1999) (31)
- Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis (1999) (30)
- Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I (2013) (30)
- c-myc and c-myb expression in acute myelogenous leukemia. (1992) (28)
- Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia (2007) (28)
- Telomerase Activity In Preleukemia And Acute Myelogenous Leukemia (2000) (28)
- Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study (1989) (27)
- High expression of transforming growth factor-beta long cell cycle times and a unique clustering of S-phase cells in patients with acute promyelocytic leukemia. (1992) (27)
- Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. (1992) (26)
- Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS). (2007) (26)
- Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. (1992) (26)
- Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study (1993) (26)
- Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). (2017) (25)
- Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philadelphia translocations. (1987) (25)
- Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). (2007) (24)
- Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients (2002) (24)
- Biologic characteristics of 164 patients with myelodysplastic syndromes. (1999) (24)
- Tumor Necrosis Factor-α Levels Decrease with Anticytokine Therapy in Patients with Myelodysplastic Syndromes (1998) (24)
- In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies. (1992) (24)
- Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease (2012) (24)
- Combination of classical and interphase cytogenetics to investigate the biology of myeloid disorders: detection of masked monosomy 7 in AML. (1993) (23)
- A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) (2012) (23)
- High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM). (2004) (23)
- The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. (2012) (22)
- Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome. (2009) (22)
- Utility and sensitivity of anti BrdU antibodies in assessing S‐phase cells compared to autoradiography (1985) (22)
- Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS) (2012) (22)
- Hypothesis: myelodysplastic syndromes may have a viral etiology. (1998) (21)
- The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failure (1991) (21)
- Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities. (2006) (20)
- Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia (1991) (20)
- A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr. (1987) (20)
- SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes (2020) (19)
- Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival, (2011) (19)
- Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts. (1987) (19)
- Changes observed in the growth fraction, labeling index, duration of S phase, and total cell cycle times of HL-60 cells as they undergo differentiation in response to retinoic acid. (1988) (19)
- Presence of activation-related m-RNA for EBV and CMV in the bone marrow of patients with myelodysplastic syndromes. (2001) (18)
- Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes (1998) (18)
- Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study. (2009) (17)
- Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome (2012) (17)
- Translocation t(6;9)(p23;q34) in acute nonlymphocytic leukemia. Two new patients without increased bone marrow basophils. (1988) (17)
- Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes. (2018) (17)
- Treatment of myeloid blastic crisis of chronic myelogenous leukemia. (1984) (17)
- Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. (2011) (17)
- The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients. (1997) (17)
- Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia [letter] (1991) (16)
- Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T‐cell expansion (2007) (16)
- Contribution of in vivo proliferation/differentiation studies toward the development of a combined functional and morphologic system of classification of neoplastic diseases (1992) (16)
- MDS: Refining existing therapy through improved biologic insights. (2012) (16)
- Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. (1987) (16)
- Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features (2010) (16)
- Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients (2000) (16)
- The selective use of AMSA following high‐dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup Study (1992) (16)
- Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia. (1995) (15)
- Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1 (2000) (15)
- Rewriting the rules for care of MDS and AML patients in the time of COVID-19 (2020) (15)
- Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q. (2006) (15)
- Immunomodulatory drugs in myelodysplastic syndromes (2006) (15)
- Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes (2006) (15)
- A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. (2013) (14)
- Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial. (2016) (14)
- Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. (2003) (14)
- Targeted therapies in myelodysplastic syndromes: ASH 2003 review. (2004) (14)
- Proto-oncogene transcript levels and acute nonlymphocytic leukemia. (1987) (14)
- Analysis of cell cycle characteristics and course of the disease in ANLL (1987) (14)
- Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia (1998) (13)
- Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease. (1984) (13)
- Phenylbutazone-induced myelodysplastic syndrome with Philadelphia translocation. (1987) (13)
- S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS) (2019) (13)
- Initial transforming event in myelodysplastic syndromes may be viral: case for cytomegalovirus (1998) (13)
- A t(1;11) in acute nonlymphocytic leukemia FAB type M4. (1987) (12)
- The treatment of patients with acute nonlymphocytic leukemia in remission. (1985) (12)
- The biology of myelodysplastic syndromes: unity despite heterogeneity (2010) (12)
- Cytokines, molecular biological abnormalities, and acute myelogenous leukemia. (1997) (12)
- In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias. (1985) (11)
- Clinical and prognostic significance of in vivo differentiation in acute myeloid leukemia (1993) (11)
- Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia (1993) (11)
- Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes (2011) (11)
- A permanent method of detecting SCE by immunofluorescence using monoclonal anti-BrdU antibodies. (1985) (10)
- Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group. (2001) (10)
- Complete Remissions Observed in Acute Myeloid Leukemia Following Prolonged Exposure to SGN-33 (lintuzumab), a Humanized Monoclonal Antibody Targeting CD33. (2007) (10)
- Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis (2021) (10)
- Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive (2018) (10)
- Improving Treatment for Myelodysplastic Syndromes Patients (2018) (10)
- An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system. (1993) (10)
- Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes (2008) (10)
- Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. (1998) (10)
- Autologous bone marrow transplantation for acute leukemia in remission. (1987) (10)
- Breakpoint cluster region rearrangements in chronic myelogenous leukemia with a masked Philadelphia chromosome. (1987) (10)
- Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples (2011) (9)
- Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia. (2008) (9)
- Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure (2010) (9)
- Increased Levels and Activity of E2F1 Transcription Factor in Myelodysplastic Bone Marrow (2004) (9)
- Four cases with complex Philadelphia translocations, including one with appearance de novo of a "masked" Ph. (1987) (9)
- Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response (2010) (9)
- Spontaneous remission in acute nonlymphocytic leukemia. (1985) (9)
- Leukaemogenesis inducedbyanactivating b-catenin mutation in osteoblasts (2014) (9)
- In situ localization of transforming growth factor beta and S-phase cells in patients with acute myeloid leukemia and myelodysplastic syndrome. (1992) (9)
- Cell Cycle Parameters as Biological Predictors of Prognosis in AML: A Review and Update of Cell Cycle Kinetics and Remission Induction/Duration in Acute Leukemia (1992) (8)
- Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. (2012) (8)
- Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) (2017) (8)
- The study of acute leukemia cells by means of acridine orange staining and flow cytometry. (1994) (8)
- A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). (2009) (8)
- Clustering in the incidence of myelodysplastic syndromes. (2007) (8)
- ON BAYESIAN ANALYSIS OF THE EXPONENTIAL SURVIVAL TIME ASSUMING THE EXPONENTIAL CENSOR TIME (2011) (8)
- A comparison of the rate of DNA synthesis in myeloblasts from peripheral blood and bone marrows of patients with acute nonlymphocytic leukemia. (1988) (7)
- Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. (1993) (7)
- INCREASED MACROPHAGES, HIGH SERUM M‐CSF AND LOW SERUM CHOLESTEROL IN MYELODYSPLASIA AND KAWASAKI DISEASE (1999) (7)
- Remission Duration in Acute Nonlymphocytic Leukemia: Practical and Theoretical Considerations (1984) (7)
- Detection of unexpected clones of monosomy 7 in childhood acute lymphoblastic leukemia using fluorescence in situ hybridization. (1994) (7)
- Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions. (1992) (7)
- [Treatment of acute nonlymphocytic leukemia]. (1991) (7)
- The Effects of the Farnesyl Transferase Inhibitor FTI L-778,123 on Normal, Myelodysplastic, and Myeloid Leukemia Bone Marrow Progenitor Proliferation In Vitro (2003) (7)
- A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results (2008) (7)
- The role of emerging technologies in the diagnosis and staging of neoplastic diseases (1992) (7)
- Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses (2013) (6)
- Low-dose decitabine and high-risk MDS. (2006) (6)
- Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results. (2005) (6)
- Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias. (1989) (6)
- Cell cycle studies in acute myelogenous leukemia. (1992) (6)
- Cell-cycle characteristics - alterable determinants of remission duration in a study of 179 standard risk newly diagnosed patients with acute myeloid-leukemia. (1993) (6)
- Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients. (2013) (6)
- Effects of Vitamin-A on Growth Traits, Immunoregulatory Organs and Immune Response in Broiler Chicken (1997) (6)
- Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia (2022) (6)
- Translational research in myelodysplastic syndromes. (2004) (6)
- Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS). (2007) (6)
- Encouraging Improvement in Cytopenias of Patients With Myelodysplastic Syndromes With Thalidomide (2000) (5)
- Assessment of cell-cycle effects of cytokines in vivo. (1992) (5)
- Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm (2006) (5)
- Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment (2017) (5)
- Interleukin-1 beta expression and treatment outcome in acute myelogenous leukemia. (1991) (5)
- Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. (2007) (5)
- Thrombocytosis in Myelodysplastic Syndromes: Not an Innocent Bystander (2012) (5)
- Comparison ofin vitro assays for detecting subpopulations of P388 leukemic cells resistant to AraC (1984) (5)
- Survey and evaluation of mutations in the human KLF1 transcription unit (2018) (5)
- Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. (1993) (5)
- Phase 1 Dose Escalation Study of TLK199 Tablets (Telintra), a Novel Glutathione Analog, in Myelodysplastic Syndrome. (2007) (5)
- The Premyelodysplastic State and the Secondary Hematologic Disorders (1998) (5)
- The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the FMS and MYC proto-oncogenes. (1994) (5)
- A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF). (2007) (5)
- Isolation of specific and biologically active peptides that bind cells from patients with acute myeloid leukemia (AML) (2008) (4)
- Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside (1985) (4)
- A t (11;21) (13;q22) in Ph-positive chronic myelogenous leukemia. (1988) (4)
- Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody (1991) (4)
- Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2020) (4)
- Evolving concepts in myelodysplastic syndromes. (2001) (4)
- Defective ribosome biogenesis in myelodysplastic syndromes (2009) (4)
- Cytokine production by in vitro processed and unprocessed haematopoietic cells. (2000) (4)
- ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size. (2009) (4)
- MYELODYSPLASTIC SYNDROMES MAY HAVE AN INFECTIOUS ETIOLOGY (2000) (3)
- Cell cycle characteristics in myeloid leukemias. (1989) (3)
- Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (2006) (3)
- Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I. (2016) (3)
- O-38 Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013; revlimid) in transfusion dependent (TD) MDS with chromosome 5Q31.1 deletion: Results of the multicenter MDS-003 study* (2005) (3)
- Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2018) (3)
- Cellular dynamics of leukemias. (1990) (3)
- Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) (2012) (3)
- Leukemia with inv ( 16 )-SMMHC in Acute Myelogenous β ( p 15 ) by CBF INK 4 b Methylation-Independent Silencing of the Tumor Suppressor (2007) (3)
- Iron Parameters in 84 MDS Patients Enrolled in a Deferasirox (Exjade®, ICL670) Multicenter Trial. (2006) (3)
- 155 Successful anti-cytokine based approach to treat myelodysplastic syndromes (MDS) (1997) (3)
- Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays. (2009) (3)
- Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells (2022) (3)
- Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukaemia. (1994) (3)
- Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results, (2011) (3)
- Immunofluorescent staining method for use with monoclonal antibodies (1984) (3)
- Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2019) (3)
- P-121 Lenalidomide (CC-5013; revlimid™)-inducedred blood cell (RBC) transfusion-independence (TI) responses in low-/INT-1-risk patients with myelodysplastic syndromes (MDS): Results of the multicenter mds 002 study (2005) (3)
- On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) (2021) (3)
- Improvement in cytopenias of patients with myelodysplastic syndromes (Mds) In response to thalidomide (2000) (3)
- Improved rapid autoradiography with elimination of background (1985) (3)
- Novel multicancer early detection technology-potential value to employers and the workforce. (2020) (3)
- Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes (2011) (3)
- A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes. (2012) (3)
- In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia. (1984) (2)
- Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes. (2016) (2)
- Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia: Directions For The New Millennium (2012) (2)
- Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2016) (2)
- Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I) (2011) (2)
- Effects of rhGM-CSF on myeloid clonogenic cells in acute myelogenous leukemia patients. (1993) (2)
- Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival (2010) (2)
- Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS). (2009) (2)
- A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies (2014) (2)
- Multi-lineage response to a combination of gingerol and curcumin in low risk myelodysplastic syndromes (MDS). (2008) (2)
- 51. Alteration of Myb and Myc expression in acute myelogenous leukemia cells (AML) in vivo in patients (1992) (2)
- The third coming: Thalidomide and a final goodbye (2002) (2)
- Developments in the treatment of transfusion- dependent anemia in patients with myelodysplastic syndromes: epidemiology, etiology, genetics, and targeted therapies (2014) (2)
- Effects of rGM‐CSF on leukemia cell proliferation and on the incorporation of cytosine arabinoside into DNA (1991) (2)
- Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia (2001) (2)
- Progress toward predictive models for the outcome of treatment for acute nonlymphocytic leukemia. (1987) (2)
- Detection of BrdU in the regenerating bone marrow cells of a patient with AML. (1989) (2)
- Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (2010) (2)
- Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS) (2005) (2)
- Two different “tales” of ATG7: Clinical relevance to myelodysplastic syndromes (2016) (2)
- Pharmacotherapy of myelodysplastic syndromes (2010) (2)
- The serial study of c-myc expression in bone marrow biopsy specimens during treatment for acute myelogenous leukaemia. (1993) (2)
- Validation of IPSS criteria in more than 1,600 MDS patients (2007) (1)
- Cell cycle and clinical characteristics of patients with acute myeloid leukemia and myelodysplasia whose biopsies are reactive with anti-factor VIII antibody. A Leukemia Intergroup Study. (1991) (1)
- Is IL 1-beta involved in the intramedullary apoptotic death of marrow cells in myelodysplastic syndromes? (1995) (1)
- Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia (2015) (1)
- Complex cytogenetic changes in Ph-negative chronic myelogenous leukemia. (1988) (1)
- Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). (2006) (1)
- Ara-C incorporation into DNA [letter] (1985) (1)
- Induction of apoptosis by TLK199 in human leukemia cells (2008) (1)
- Thrombocytosis in Myelodysplastic Syndromes: Not an Innocent (2012) (1)
- A Pluralistic Approach to the Study of Myelodysplastic Syndromes: Evolving Pathology of the Seed via the Soil (2011) (1)
- Selection of optimal remission consolidation therapy for individual patients with acute myelogenous leukemia (2000) (1)
- Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes? (2006) (1)
- Lack of relationship between in vitro cell measurements and response to busulfan in chronic myelocytic leukemia (1985) (1)
- Three Cases of Refractory Anemia with Ringed Sideroblasts Who Responded toChloroquine (2014) (1)
- Marrow cytokine transcripts and the secondary hematologic disorders. (1999) (1)
- Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS) (2014) (1)
- Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (2011) (1)
- Current View of miRNA with Tumor Suppressor Function, Exploring MDS and AML as Models (2014) (1)
- Molecular Genetic Analysis of Myelodysplastic Syndromes (MDS) Patients with Ring Sideroblasts (RS); Independent Confirmation of Association of SF3B1 Mutations with Better Prognosis (2014) (1)
- Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199) (2011) (1)
- Letter to the editor: translocation (7;21)(p14;q11) in Ph-positive chronic myelogenous leukemia (1988) (1)
- 121. Effects of retinoic acid, interferon and granulocyte-macrophage colony stimulating factor on human leukemic cells and the hematopoietic microenvironment in vivo (1992) (1)
- A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia (2021) (1)
- tipifarnib in intermediate- to high-risk myelodysplastic syndrome A multicenter phase 2 study of the farnesyltransferase inhibitor (2012) (1)
- Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer (2016) (1)
- Arsenic Trioxide (Trisenox®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI). (2004) (1)
- Rigosertib in myelodysplastic syndromes (MDS) (2016) (1)
- Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results (2007) (1)
- Prognostic value of low platelets in MDS patients with del(5q) (2007) (1)
- Loss of TET2 Function in Myelodysplastic Syndrome Results in Intragenic Hypermethylation and Alterations in mRNA Splicing (2014) (1)
- Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation. (2005) (1)
- 76 The absolute number of CD34+ cells and CD34+ cells in S-phase increase during the evolution of myelodysplastic syndromes (MDS) (1997) (1)
- An Erythroid Differentiation Gene Expression Signature Predicts Response to Lenalidomide in Myelodysplasia. (2006) (1)
- C-reactive protein (CRP) associated with higher risk patients with myelodysplastic syndromes (MDS) (2008) (1)
- Thrombocytopenia Predicts for Poor Survival In Patients with Lower Risk Myelodysplastic Syndromes (MDS) (2010) (1)
- Pharmacological Targeting of Osteoblast-Induced MDS and AML (2018) (1)
- Lenalidomide for myelodysplastic syndromes: finally, hope not hype (2005) (1)
- Effects of 13 cis Retinoic Acid(RA) and ainterferon(IFN) on Chronic Myelogenous Leukemia (CML) in vivo in Patients (1995) (1)
- Low incidence of JAK2 and FLT3 mutations in patients with chronic myelomonocytic leukemia (CMML) (2006) (1)
- Prognosis in myelodysplastic syndromes: Are the new classifications useful? (2008) (1)
- Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia (2004) (0)
- A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies (2016) (0)
- Serum cytokine levels in patients with myelodysplastic syndromes (2001) (0)
- Novel Therapies with Biologic Response Modifiers to Reverse Extremely High Apoptosis in Myelodysplastic Syndromes (MDS) (1995) (0)
- Abstract A25: A niche directed therapy for the treatment of myelodysplasia and acute myeloid leukemia (2023) (0)
- Abstract 556: Highly complex DNA sequencing library preparation for cfDNA enrichment panels using a single-stranded approach (2021) (0)
- INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME. (2016) (0)
- A Pilot Application of SELDI Serum Proteomics in Bone Marrow Failure Syndromes. (2004) (0)
- Survey and evaluation of mutations in the human KLF1 transcription unit (2018) (0)
- Abstract 2425: An in vitro platform to dissect drug responsiveness in refractory anemia with ringed sideroblasts (RARS) (2015) (0)
- A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF). (2007) (0)
- Fungal infection masquerading as acute pulmonary embolization. (1986) (0)
- The Clinical and Biologic Significance of Thrombocytosis in Myeloid Disorders (2011) (0)
- myelogenous leukemia (letter) Interleukin-1 beta expression and treatment outcome in acute (2011) (0)
- Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS). (2016) (0)
- Response : Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia (2006) (0)
- Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5 q-syndrome RUNNING TITLE : COOPERATIVE LOSS OF MIR-145 AND RPS 14 IN 5 Q-MDS (2011) (0)
- A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD). (2006) (0)
- Neoplastic Progression of the Myeloid Leukemias (1989) (0)
- 2022 – A NICHE-DIRECTED THERAPEUTIC APPROACH TARGETING MDS AND AML (2021) (0)
- Complete blood count may provide risk stratification for survival and AML transformation in CMML (2007) (0)
- [Myelodysplastic syndromes]. (1997) (0)
- Extremely high incidence of apoptosis may explain ineffective hematopoiesis in myelodysplastic syndromes (MDS) (1994) (0)
- Expression of Proliferation Related Genes in Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) Patients with Resistance to Low Dose Vidaza and Thalidomide. (2006) (0)
- MtDNA Sequence of MDS Patients Treated with CoQ10. (2005) (0)
- Pilot study of SELDI-TOF (surface enhanced laser desorption/ionization time of flight) in bone marrow failure syndromes (2005) (0)
- A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies. (2015) (0)
- Problems associated with the study of cytokines in patients with leukaemia. (1992) (0)
- The biology and treatment of myelodysplastic syndromes. (2013) (0)
- Myelodysplastic Syndromes: From Biology To Therapy (1999) (0)
- 162 Potential for use of amifostine in the treatment of poor prognosis acute myelogenous leukemia (1997) (0)
- Kinetic Resistance, Regrowth Resistance, and Multidrug Resistance in the Treatment of Acute Myelogenous Leukemia (AML) (1996) (0)
- A novel method for single cell detection of in situ telomerase or histone H3 in combination with clonal analysis by FISH. (2003) (0)
- 288 Point mutations in myelodysplastic syndromes: Associations with clinical features and independent predictors of overall survival (2011) (0)
- normal and disordered erythropoiesis in vivo (2017) (0)
- OPEN FORUM A paradigm shift in myelodysplastic syndromes (2019) (0)
- Methylation-Independent Silencing of the Tumor Suppressor p15INK4B by CBFb-SMMHC in Acute Myeloid Leukemias with inv(16). (2005) (0)
- Activity of Lenalidomide in a Phase II Single Institution Study in Non-Del(5q) Transfusion Dependent, Patients with Low and Intermediate-1 Risklower-Risk, Non-Del(5q) Myelodysplastic Syndromes (MDS))): Results From a Single-Institution Phase II Study (2012) (0)
- A humanized unconjugated antibody targeting CD33 (SGN-33; huM195) is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). (2006) (0)
- 22 Pneumoperitoneum following CT guided percutaneous lung biopsy (2016) (0)
- Encouraging hematopoietic and cytogenetic responses to coenzyme Q10 (coQ10) in patients with low and intermediate-1 risk (Int-1) myelodysplastic syndromes (MDS (2005) (0)
- Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study (2022) (0)
- Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance (2022) (0)
- Coordinate loss of a microRNAand protein-coding gene cooperate in the pathogenesis of 5qsyndrome (2016) (0)
- Patients with Myeloid Leukemias Expression of Nucleolar Antigen p 145 in Bone Marrow Cells of Updated (2006) (0)
- 167. The proliferative rates of acute myelogenous leukemia cells can be accelerated or slowed in vivo in patients (1992) (0)
- The First Cell (2019) (0)
- Prognostic significance of bone marrow cellularity in myelodysplastic syndromes: a retrospective analysis. (2016) (0)
- Abstract IA6: Misregulation of pre-mRNA splicing in cancer (2013) (0)
- Ghalib: Epistemologies of Elegance (2009) (0)
- 3061 – STROMAL CELL-TRIGGERED DOWNREGULATION OF THE NUCLEOPORIN (NUP) FAMILY DRIVES TRANSFORMATION OF MYELODYSPLASIA TO ACUTE MYELOID LEUKEMIA (2022) (0)
- Drug shows the potential for long-term relief from a type of chronic leukemia (2021) (0)
- by osteoblasts Inhibition of leukemia cell engraftment and disease progression in mice (2014) (0)
- Translocation (7;21)(p14;q11) in Ph-positive chronic myelogenous leukemia. (1988) (0)
- 92 Stem cell defect and the genesis of cytopenias in myelodysplastic syndromes (MDS) and their correction by amifostine (1997) (0)
- Myelodysplastic Syndromes – Unexpected Insights Stimulate the Biological Landscape (2010) (0)
- Ara-C incorporation into DNA. (1985) (0)
- Peer Review (2014) (0)
- Abnormalities in the expression of the P15 tumor suppressor gene and in cytokine production during the development of secondary hematologic disorders (2000) (0)
- A Pilot Study To Test the Efficacy of a Combination of Gleevec with Thalidomide in Patients with Idiopathic Primary Myelofibrosis, Myelofibrosis with Myeloid Metaplasia and Myelodysplastic Syndromes Who Present with Myelofibrosis. (2006) (0)
- Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies (2016) (0)
- Iron Overload—Screening and Diagnosis (2006) (0)
- Abstract 2989: Loss of methylation in a regulatory region of BCL2 in MDS/AML. (2013) (0)
- A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation (2016) (0)
- 23. Cytokines/stromal cells in hematopoietic microenvironment influence proliferation/differentiation of acute myeloid leukemia cells (1992) (0)
- Eosinophilia With FIP1L1-PDGFΡA Fusion in a Patient With Chronic Myelomonocytic Leukemia (2008) (0)
- Survival Analysis of Myelodysplastic Syndrome (MDS) Patients with Abnormal Karyotype - A Single Group Experience (2012) (0)
This paper list is powered by the following services:
Other Resources About Azra Raza
What Schools Are Affiliated With Azra Raza?
Azra Raza is affiliated with the following schools:
- University of Cincinnati
- MD Anderson Cancer Center
- King Edward Medical University
- University of Southern California
- University of Chicago
- University of Massachusetts Medical School
- Columbia University
- Dow Medical College
- Ohio State University
- University of Washington
- Rush University
- University of Massachusetts
- Harvard University
